Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (“Tandem” or the “Company”), a global diabetes technology company, today announced the appointment of Jeannette Bankes as president and chief executive officer (“CEO”), and a member of its Board of Directors, effective November 16, 2026. Ms. Bankes will succeed John Sheridan, who will retire at the end of 2026 after more than a decade of service to Tandem, as part of a planned leadership transition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105587802/en/
Jeannette Bankes named President and Chief Executive Officer for Tandem Diabetes Care.
Mr. Sheridan has served as Tandem’s president and CEO since 2019, after joining the Company as chief operating officer in 2013. During his tenure, Tandem launched a portfolio of automated insulin delivery solutions, while strengthening the organization’s ability to operate on a global scale, and has initiated business model changes to simplify and improve technology access. Mr. Sheridan will remain with the Company as an employee through the end of 2026, then will serve as a consultant to support a smooth transition.
Ms. Bankes brings more than 30 years of global operating experience and a strong record of translating strategy into consistent execution and growth. Her customer-focused approach and commitment to innovation align with Tandem’s mission and priorities as the Company advances its technology roadmap, broadens access and pursues sustainable, profitable growth. Her appointment follows a Board-led succession and search process designed to ensure continuity as Tandem executes its strategy.
“On behalf of the Board, I thank John for his significant contributions and dedication to our customers, employees and shareholders. He established Tandem as a global leader in diabetes technology and positioned the Company for its next phase of growth,” said Beckie Robertson, Chair of Tandem’s Board of Directors. “Jeannette is the right CEO to build on this foundation. Her broad operating experience, focus on the people we serve and ability to translate innovation into impact will be critical as we seek to deliver new technology and drive profitable growth.”
“It has been a privilege to serve as Tandem’s CEO and work alongside a dedicated organization united by our mission to improve the lives of people with diabetes, including half a million people worldwide who benefit from Tandem’s technology,” said Mr. Sheridan. “Jeannette is an exceptional leader, and I am confident that she and the Tandem team have the capability, passion and commitment to guide the Company into its next chapter.”
“Tandem’s compelling mission, differentiated portfolio and global reach create a meaningful opportunity to improve the lives of more people with diabetes,” said Ms. Bankes. “I am excited to work alongside the talented people at Tandem to build on these strengths, advance the innovation pipeline and expand access to our technology. Through disciplined execution and a continued focus on customers, we can extend Tandem’s impact and deliver lasting value for the diabetes community and shareholders.”
Inducement Award
In connection with the hiring of Ms. Bankes, upon recommendation of the Compensation Committee after consultation with the committee’s independent compensation consultant, the Board approved the grant of an inducement award consisting of restricted stock units (“RSUs”), which will cover a number of shares of Tandem common stock (“Common Stock”) having an aggregate value as close as practicable to, but not exceeding, $10,000,000, based on the average closing price of the Common Stock as reported on the Nasdaq Global Market during the 15-trading-day period ending on the fifth trading day before the Grant Date (as defined below). The grant of RSUs will be effective December 15, 2026 (the “Grant Date”), and one-third of the shares subject to the RSUs will vest on the first anniversary of the Grant Date, with the remaining two-thirds vesting in eight equal quarterly installments thereafter.
The RSUs described above will be subject to the terms of Tandem’s 2023 Long-Term Incentive Plan, as amended (the “Plan”), but will be granted outside of the Plan as an inducement material to Ms. Bankes’ entering into employment with Tandem in accordance with Nasdaq Listing Rule 5635(c)(4). Such grant was intended in part to compensate Ms. Bankes for the value of unvested equity-based awards forfeited upon departure from her previous employer. Further information will be disclosed in the Company’s proxy statement for its 2027 Annual Meeting of Stockholders.
About Jeannette Bankes
Ms. Bankes is a proven leader with extensive experience at publicly traded companies in the healthcare industry, including GE HealthCare, Merck, Boston Scientific and Alcon. For more than 30 years, Ms. Bankes has held senior roles spanning product management, marketing, sales, clinical and regulatory strategy, medical affairs, operations and manufacturing. Her focus on patients and clinicians, and commitment to developing technologies that address real-world needs, have consistently translated innovation into measurable improvements in care. Most recently, she served as president and chief executive officer of GE HealthCare’s Patient Care Solutions segment, a $3.1 billion business that spans monitoring, diagnostic cardiology, maternal infant care and anesthesia solutions. In this role, Ms. Bankes drove growth and profitability across the portfolio, building on her track record of bringing new technologies to market and scaling global businesses. Previously, she served as senior vice president and president of global franchises at Alcon, overseeing product development, portfolio management and commercialization across its surgical, vision care and ocular health businesses. Ms. Bankes holds a bachelor’s degree in medical technology from Kutztown University.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the leadership transition and its timing, Tandem’s strategic priorities, technology roadmap, pipeline and development timelines, commercial performance, growth, profitability and future operating results. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks associated with ongoing market acceptance of the Company’s products; products marketed and sold or under development by competitors; the Company’s ability to establish and sustain operations to support international sales, including expanding into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to successfully commercialize its products; the Company’s ability to develop and launch new products; risks associated with the regulatory approval process internationally for new products; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable, or may otherwise negatively impact the purchasing trends of customers; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; risks associated with the potential loss of key personnel; and other risks identified in Tandem’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Tandem undertakes no obligation to update any forward-looking statement, except as required by law.
©2026 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261105587802/en/
Media gallery
